A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

In recent years, high-dose psilocybin has gained attention for its potential therapeutic benefits in many psychiatric indications, however existing clinical data for low psilocybin doses are limited.

Microdoses are generally considered to be those absent of profound sensory and cognitive effects that would interfere with normal everyday functioning, but only a small number of prospective studies have evaluated microdoses and/or low doses in a controlled manner.

As a foundational study of the therapeutic use of low doses of psilocybin, this study will evaluate the safety, tolerability, pharmacokinetics, and sensorial effects using a prospective, controlled, single ascending dose/multiple ascending doses in healthy volunteers.

Key Inclusion Criteria:

• Males or females aged 18 to 65 years old (inclusive) at the time of signing the informed consent form. Standard contraception measures are required for this clinical trial.
• Healthy, in the opinion of the Investigator, based on prior (history of) or current (ongoing) medical and psychiatric screening assessments.
• Participants with no clinically significant findings on physical examination, laboratory tests, and cardiac assessment.
• Body mass index (BMI) within the range 18-32 kg/m2, inclusive.
• Normal blood pressure.
• Capable of giving signed informed consent which includes the requirements and restrictions as per the approved study protocol.

Key Exclusion Criteria:

• Prior known exposure to psilocybin within the past 10 years.
• Prior (history of) or current (ongoing) diagnosis, or first-degree relatives with clinically significant medical or psychiatric condition or disease.
• History of or presence of cardiovascular disease.
• Abnormal and clinically significant ECG.
• History or presence of a neurodegenerative disorder such Alzheimer's disease or Parkinson's disease.
• Use of medications that have CNS effects or affect performance.
• Use of medications with serotonergic activity.
• History or presence of hypersensitivity or idiosyncratic reaction to psilocybin or related compounds.
• History of substance or alcohol abuse disorder in the last 1 year.
• Participant who, for any reason, is deemed by the Investigator to be inappropriate for this study; or has any condition which would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational drug; or is unable to comply with the study protocol.